Research programme: anticancer DARPin therapeutics - Molecular Partners

Drug Profile

Research programme: anticancer DARPin therapeutics - Molecular Partners

Alternative Names: MP 0274; Multispecific-DARPins - Molecular Partners

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator Molecular Partners AG
  • Class Proteins
  • Mechanism of Action Apoptosis stimulants; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 23 Mar 2017 Molecular Partners plans a phase I trial for Neoplasms (NCT03084926)
  • 06 Dec 2016 Pharmacokinetics and pharmacodynamics data from preclinical studies in Cancer presented at the 39th Annual San Antonio Breast Cancer Symposium (SABCS-2016)
  • 27 Oct 2016 Molecular Partners intends to file an IND application for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top